UFP Technologies CEO R. Jeffrey Bailly to Retire in 2026, Transitioning to Executive Chairman
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 02 2025
0mins
Should l Buy UFPT?
UFP Technologies announced that R. Jeffrey Bailly will retire as CEO at the Company's next annual meeting on June 4, 2026. At that time, Mitchell Rock, President of the Company, will assume the CEO position and join the Company's Board. To facilitate a smooth transition, Bailly will serve as Executive Chairman of the Board for the following year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UFPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UFPT
About UFPT
UFP Technologies, Inc. is a designer and custom manufacturer of solutions for medical devices, sterile packaging, and other engineered custom products. The Company’s single-use and single-patient devices and components are used in a range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants. Its manufacturing operations consist primarily of cutting, routing, compression and injection molding, vacuum-forming, micro-molding, thermoforming, laminating, radio frequency and impulse welding, and assembling. It also engineers components for automotive use in interior trim and structural applications. These components are produced using a compression molding process to create functional composites consisting of various materials such as polypropylene/fiberglass panels, nonwovens, and fabrics. It also develops and manufactures precision thermo-formed and heat-sealed polymer components.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UFP Technologies Reports Q1 Adjusted EPS of $2.48, Exceeding IBES Estimate of $2.25
- Q1 Adjusted EPS: The adjusted earnings per share (EPS) for Q1 is reported at USD 2.48.
- IBES Estimate: This figure exceeds the IBES estimate, which was USD 2.25.
See More
UFP Technologies Q1 2026 Earnings Call Insights
- Revenue Growth: UFP Technologies reported a 4.1% revenue increase in Q1 2026, with medical sales up 5.9% while non-medical sales declined by 15%, indicating a strategic focus on high-growth segments in the MedTech space amidst shifting market demands.
- New Program Developments: The company successfully launched four new programs, with three customers requesting to double their capacity, suggesting strong market demand and the potential for robust revenue growth in the second half of the year.
- Cost and Profitability Pressures: Although gross margin improved slightly to 28.8%, profitability was pressured by startup costs, AJR labor inefficiencies, and legal expenses related to a cyberattack, highlighting challenges faced during the expansion phase.
- Future Outlook: Management anticipates accelerated revenue growth in the second half of the year, particularly driven by new programs, while also planning to expand capacity in the APAC region to meet future market demands.
See More
UFP Technologies Q1 Earnings Beat Expectations
- Earnings Beat: UFP Technologies reported a Q1 non-GAAP EPS of $2.48, exceeding expectations by $0.17, indicating enhanced profitability that may attract more investor interest.
- Revenue Miss: The company's revenue of $154.2 million, while up 4.1% year-over-year, fell short of expectations by $0.58 million, reflecting challenges in market demand that could impact future growth outlook.
- Slight Operating Income Increase: Operating income rose 1.0% to $23.4 million in Q1, demonstrating the company's efforts in cost control and efficiency improvements, although the growth rate remains modest.
- Stable Adjusted Operating Income: Adjusted operating income for Q1 remained flat at $25.8 million compared to the same period last year, indicating stability in profitability but a lack of significant growth momentum.
See More
UFP Technologies to Report Q1 Results on May 4
- Earnings Report Schedule: UFP Technologies plans to release its Q1 earnings report on May 4, 2026, after market close, reflecting the company's ongoing commitment to transparency in the medical device sector.
- Conference Call Timing: The company will hold a conference call on May 5, 2026, at 8:30 AM Eastern Time to discuss the earnings details and address investor inquiries, enhancing engagement with stakeholders.
- Participation Details: Investors can join the call using the toll-free number 1-412-206-6478 for USA/Canada or 1-833-890-4010 for international participants, ensuring broad access to the discussion and information dissemination.
- Webcast and Replay Availability: A live webcast of the conference call will be available, with accompanying materials posted online, and a replay will be accessible on the company's Investor Relations website, further improving information accessibility and transparency.
See More
Strait of Hormuz Reopening Boosts Healthcare Stocks
- Oil Price Impact on Healthcare Costs: The reopening of the Strait of Hormuz has led to a decrease in global logistics and energy costs, directly reducing operational expenses for healthcare providers and medical device manufacturers, thereby enhancing profit margins and improving quarterly earnings outlooks.
- Risk Appetite Resurgence: The ceasefire has sparked a 'risk-on' sentiment, driving investors back into high-growth biotech and pharmaceutical stocks, which is expected to facilitate funding for long-term R&D and clinical trials that were previously hindered by macroeconomic uncertainties.
- Reduced Market Volatility: As broader market volatility recedes, investor confidence in elective procedures and pharmaceutical demand strengthens, with expectations that this trend will continue through 2026, further stabilizing the global economy.
- Natera's Stock Volatility: Natera's shares have experienced 13 moves greater than 5% in the past year; today's 5.4% increase indicates market recognition of the news's significance, yet the stock remains down 8.9% year-to-date, trading 18.1% below its 52-week high.
See More
UFP Technologies Shares Enter Oversold Territory
- Oversold Signal: UFP Technologies Inc. has an RSI of 29.9, indicating that the stock may be nearing a bottom after significant selling, prompting investors to consider buying opportunities.
- Price Fluctuation: The stock hit a low of $207.475, with the current trading price at $210.58, showing some recovery from the 52-week low of $178.26, reflecting cautious optimism about its future performance.
- Market Comparison: Compared to the S&P 500 ETF's current RSI of 46.1, UFP's oversold condition may attract investors looking for a rebound, highlighting a divergence in market sentiment.
- Historical Performance: UFP's 52-week high is $274.93, and the current price still has a significant gap from this peak, indicating potential rebound space and investment value.
See More
UFP Technologies Reports Q1 Adjusted EPS of $2.48, Exceeding IBES Estimate of $2.25
- Q1 Adjusted EPS: The adjusted earnings per share (EPS) for Q1 is reported at USD 2.48.
- IBES Estimate: This figure exceeds the IBES estimate, which was USD 2.25.
See More
UFP Technologies Q1 2026 Earnings Call Insights
- Revenue Growth: UFP Technologies reported a 4.1% revenue increase in Q1 2026, with medical sales up 5.9% while non-medical sales declined by 15%, indicating a strategic focus on high-growth segments in the MedTech space amidst shifting market demands.
- New Program Developments: The company successfully launched four new programs, with three customers requesting to double their capacity, suggesting strong market demand and the potential for robust revenue growth in the second half of the year.
- Cost and Profitability Pressures: Although gross margin improved slightly to 28.8%, profitability was pressured by startup costs, AJR labor inefficiencies, and legal expenses related to a cyberattack, highlighting challenges faced during the expansion phase.
- Future Outlook: Management anticipates accelerated revenue growth in the second half of the year, particularly driven by new programs, while also planning to expand capacity in the APAC region to meet future market demands.
See More
UFP Technologies Q1 Earnings Beat Expectations
- Earnings Beat: UFP Technologies reported a Q1 non-GAAP EPS of $2.48, exceeding expectations by $0.17, indicating enhanced profitability that may attract more investor interest.
- Revenue Miss: The company's revenue of $154.2 million, while up 4.1% year-over-year, fell short of expectations by $0.58 million, reflecting challenges in market demand that could impact future growth outlook.
- Slight Operating Income Increase: Operating income rose 1.0% to $23.4 million in Q1, demonstrating the company's efforts in cost control and efficiency improvements, although the growth rate remains modest.
- Stable Adjusted Operating Income: Adjusted operating income for Q1 remained flat at $25.8 million compared to the same period last year, indicating stability in profitability but a lack of significant growth momentum.
See More
UFP Technologies to Report Q1 Results on May 4
- Earnings Report Schedule: UFP Technologies plans to release its Q1 earnings report on May 4, 2026, after market close, reflecting the company's ongoing commitment to transparency in the medical device sector.
- Conference Call Timing: The company will hold a conference call on May 5, 2026, at 8:30 AM Eastern Time to discuss the earnings details and address investor inquiries, enhancing engagement with stakeholders.
- Participation Details: Investors can join the call using the toll-free number 1-412-206-6478 for USA/Canada or 1-833-890-4010 for international participants, ensuring broad access to the discussion and information dissemination.
- Webcast and Replay Availability: A live webcast of the conference call will be available, with accompanying materials posted online, and a replay will be accessible on the company's Investor Relations website, further improving information accessibility and transparency.
See More
Strait of Hormuz Reopening Boosts Healthcare Stocks
- Oil Price Impact on Healthcare Costs: The reopening of the Strait of Hormuz has led to a decrease in global logistics and energy costs, directly reducing operational expenses for healthcare providers and medical device manufacturers, thereby enhancing profit margins and improving quarterly earnings outlooks.
- Risk Appetite Resurgence: The ceasefire has sparked a 'risk-on' sentiment, driving investors back into high-growth biotech and pharmaceutical stocks, which is expected to facilitate funding for long-term R&D and clinical trials that were previously hindered by macroeconomic uncertainties.
- Reduced Market Volatility: As broader market volatility recedes, investor confidence in elective procedures and pharmaceutical demand strengthens, with expectations that this trend will continue through 2026, further stabilizing the global economy.
- Natera's Stock Volatility: Natera's shares have experienced 13 moves greater than 5% in the past year; today's 5.4% increase indicates market recognition of the news's significance, yet the stock remains down 8.9% year-to-date, trading 18.1% below its 52-week high.
See More
UFP Technologies Shares Enter Oversold Territory
- Oversold Signal: UFP Technologies Inc. has an RSI of 29.9, indicating that the stock may be nearing a bottom after significant selling, prompting investors to consider buying opportunities.
- Price Fluctuation: The stock hit a low of $207.475, with the current trading price at $210.58, showing some recovery from the 52-week low of $178.26, reflecting cautious optimism about its future performance.
- Market Comparison: Compared to the S&P 500 ETF's current RSI of 46.1, UFP's oversold condition may attract investors looking for a rebound, highlighting a divergence in market sentiment.
- Historical Performance: UFP's 52-week high is $274.93, and the current price still has a significant gap from this peak, indicating potential rebound space and investment value.
See More
